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Abstract 
Peritonitis is a major complication of peritoneal dialysis, but the relationship between peritonitis and 
mortality among these patients is not well understood. In this case-crossover study, we included the 1316 
patients who received peritoneal dialysis in Australia and New Zealand from May 2004 through December 
2009 and either died on peritoneal dialysis or within 30 days of transfer to hemodialysis. Each patient 
served as his or her own control. The mean age was 70 years, and the mean time receiving peritoneal 
dialysis was 3 years. In total, there were 1446 reported episodes of peritonitis with 27% of patients having 
≥2 episodes. Compared with the rest of the year, there were significantly increased odds of peritonitis 
during the 120 days before death, although themagnitude of this association wasmuch greater during the 
30 days before death. Compared with a 30-day window 6 months before death, the odds for peritonitis 
was six-fold higher during the 30 days immediately before death (odds ratio, 6.2; 95% confidence interval, 
4.4–8.7). In conclusion, peritonitis significantly associates with mortality in peritoneal dialysis patients. 
The increased odds extend up to 120 days after an episode of peritonitis but themagnitude is greater 
during the initial 30 days. 
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Patients on peritoneal dialysis have a high annual mortality rate. Peritonitis is also a major 
complication of peritoneal dialysis but the association between peritonitis and mortality has 
not been examined systematically. Our aim was to determine the relationship between 
peritonitis and mortality in patients on peritoneal dialysis. This was a case-crossover study 
where individual patients served as their own control. All people receiving peritoneal dialysis 
in Australia and New Zealand between 1st May 2004 and 31st December 2009 and died on 
peritoneal dialysis, or within 30 days of transfer to hemodialysis, were included. 1316 
patients were included with a mean age of 70.4±11.7 years and receiving peritoneal dialysis 
for 2.9±2.0 years. 1446 episodes of peritonitis were reported with 27% of patients having 2 or 
more episodes. A significantly increased odds of peritonitis prior to death compared with the 
rest of the year was seen up to 120 days before death, although the magnitude of this 
association was much greater in the immediate 30 days before death. The odds ratio of 
peritonitis in the 30 days prior to death compared to a 30 day window 6 months prior to death 
was 6.2 (95% confidence interval 4.4, 8.7). In conclusion, peritonitis was significantly 
associated with mortality in peritoneal dialysis patients. This increased odds extended up to 
120 days following an episode of peritonitis but the magnitude is greater in the initial 30 days 
and it may be that the latter is the preferred new definition of peritonitis-associated mortality.
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Introduction: 
Annual mortality for peritoneal dialysis (PD) patients is between 10 and 20%. 1 Infectious 
causes of death account for a variable proportion of deaths on PD, 5.9 to 33%, depending 
upon the publication examined and the population studied.1-3 The majority of these infections 
in PD patients are due to peritonitis, with rates varying between centres. It is difficult though 
to ascertain the definition of infection-, in particular peritonitis-, associated death as often it is 
a clinical diagnosis without any clearly defined criteria.  
 
The evidence that peritonitis increases a patient’s risk of death is primarily descriptive in 
nature or extrapolated from peritonitis outcomes in non-dialysis patients.4-5 There has been 
limited statistical analysis formally examining the relationship between peritonitis and death, 
primarily related to the brevity and intermittent nature of the at-risk period.6 The patient that 
has peritonitis and is septic then dies, clearly has a likely causal relationship between the two. 
However, the inflammatory state that an infection creates within an individual may also 
predispose to vascular events, especially in those with pre-existing disease, possibly leading 
to cardiovascular or cerebrovascular death.7-9 These events may even occur a period of time 
after an infection.10 
 
Our aim was to explore the relationship between mortality and peritonitis in PD patients by 
determining whether peritonitis was more likely to occur in the time immediately before 
death than in periods distant to death. We utilise a case-crossover design to compare the 




There were 1316 PD patients who died while receiving PD treatment (or within 30 days of 
transfer to hemodialysis) included in the analyses, 44% of whom were female. Patients mean 
age at death was 70.4±11.7 years, with a mean time on PD of 2.9±2.0 years (Table 1). 
Patients were predominantly Caucasian (78%), with 10.7% Asians and 8.9% Aboriginal or 
Torres Strait Islanders (ATSI). A total of 1446 peritonitis episodes were documented, with 
56% experiencing ≥1 episode, and 27% ≥2. Mortality was attributed to peritonitis in 6% of 
deaths.  The median (25th and 75th percentile) time between peritonitis episode and death 
was 247 days (64-552) (Figure 1).  
 
Of the 250 patients with an episode of peritonitis in the 30 days prior to death, 69 (27.6%) 
had peritonitis as the stated cause of death. For the remaining patients the cause of death was 
categorised as cardiac (68, 27.2%), withdrawal (40, 16%), non-peritoneal infection (20, 8%), 
cerebrovascular (13, 5.2%), malignancy (7, 2.8%), peripheral vascular events (5, 2%), and 
other causes (28, 11.2% including bowel infarction, gastrointestinal haemorrhage, cachexia 
and abdominal perforation).  
 
Determination of the duration of the ‘window’ period 
In order to ascertain the preferred duration of the window to be used in this analysis, 5- and 
7- day windows were used at intervals prior to death and the occurrence of peritonitis during 
that window was compared to all of the preceding periods up to 12 months before death 
(Figure 2a and 2b). The odds of peritonitis in any 5 day period more than 30 days prior to 
death were no different than any other early period in the year before death (Figure 2a). 
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However, patients were more than 2.5-times more likely to have peritonitis in the window 30 
days before death (95% confidence interval (CI)=1.7-3.6, P<0.001) than during any earlier 
period and the odds ratio increased to 4.1 times in the 5-days immediately before death 
(95%CI=3.2-5.3 p<0.001). A similar pattern was observed using 7-day windows, with the 
risk of peritonitis significantly increased from 28 days to 7 days immediately before death 
(odds ratio (OR) range 2.9-5.7). Since there were statistically significant odds ratios for both 
5 and 7 day windows until 30 days prior to death, 30 days was utilised as the duration of the 
windows to examine the association between mortality and peritonitis. 
 
Potential at risk period of the association between peritonitis and mortality 
Upon utilising a 30 day window at different intervals before death and comparing the 
incidence of peritonitis with all other 30 day windows in the 12 months prior to death, there 
was a significantly increased odds of peritonitis up to 120 days prior to death but the 
magnitude of this association was much greater in the first 30 days (OR=6.5, 95%CI=5.4-7.7, 
P<0.001) (Figure 2c). 
 
Magnitude of the odds of peritonitis prior to death 
In the 30 days immediately prior to death, 250 (19.0%) patients experienced an episode of 
peritonitis, compared to 88 (6.7%) in the 30 days 6 months before death. The OR of 
peritonitis in the 30 days prior to death compared to a 30 day window 6 months prior to death 
was statistically significant at 6.2 (95%CI = 4.4, 8.7) (Table 2). Similar statistically 
significant associations were seen when the comparator period was 3 and 9 months prior to 
death. 
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Association of peritonitis and cause of death specific mortality 
A significantly increased odds of peritonitis in the 30 days prior to death was detected in 
patients who died from cardiovascular, cerebrovascular or peripheral vascular disease 
(OR=3.4, 95%CI=2.4, 4.6) (Figure 3a). Similar findings were detected in patients who died 
from infectious causes and those that were coded as having withdrawn from dialysis (Figure 
3b and c). 
 
Sensitivity analysis 
Sensitivity analysis of the 30 day window demonstrated that there was no significant 
difference in the odds ratio of peritonitis at varying time periods prior to death more remote 
than the period immediately prior to death (Table 3). This was consistent when only PD 
patients with one episode of peritonitis were included. 
 
Demographic and clinical predictors of peritonitis in the 30 days prior to death 
Peritonitis in the 30 days prior to death was significantly associated with history of coronary 
artery disease, time spent on peritoneal dialysis and the number of peritonitis episodes they 
had previously. The odds ratio of peritonitis in the 30 days before death increased by 1.07 for 
each additional year spent on PD (95%CI=1.00-1.15, P=0.049), and by 1.70 for each 
additional case of peritonitis (95%CI=1.55-1.89, P<0.001). However, patients with a history 
of coronary artery disease were less likely to have peritonitis in the 30 days prior to death 
compared with those without this comorbidity (OR=0.71, (95%CI=0.51-0.99, P=0.048).  
(Table 4).  
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Discussion: 
Patients on PD have an annual mortality rate of 10-20%.1 In Australia and New Zealand, 15% 
of PD patients that died were coded as having done so due to infections, with approximately 
6% due to peritonitis.1 In fact, 19% of PD patients died with peritonitis occurring in the 
preceding 30 days. We have demonstrated that in those patients that died on PD there was an 
approximately 6-fold increase in the odds of peritonitis in the 30 days before death compared 
to the 30-day period 6 months prior to death.  
  
There is currently no standard definition of peritonitis-associated mortality. Not surprisingly 
therefore, there is appreciable variation in the reported prevalence of peritonitis-associated 
mortality in the literature, ranging from 5.9% up to 33% of deaths.2-3, 12 Although a 
proportion of this variability reflects differences in case-mix and racial origins, coding 
differences are also likely to contribute.  
 
In many cases, the diagnosis of peritonitis-associated death is made by the treating physician 
and is somewhat subjective. Some physicians may only diagnose peritonitis-associated 
mortality in cases where the patient presented with systemic manifestations of sepsis and 
immediately died, while others include all deaths following a period of time after an episode 
of peritonitis. For example, a previous series of publications from the ANZDATA Registry 
defined peritonitis-associated mortality as “death directly attributable to peritonitis in the 
clinical opinion of the treating nephrologist”.13-21 In contrast, Perez-Fontan et al defined 
peritonitis-associated mortality as death “a) during the course of a clinically active peritonitis, 
or b) during the week following complete clinical, bacteriologic, and cytological remission of 
9 
an episode of peritonitis, or c) in the case of a refractory peritonitis demanding catheter 
removal, before hospital discharge for reinitiation of regular dialysis therapy (PD or HD)”.22 
Alternatively, Szeto et  al defined peritonitis-associated mortality as “death from any cause 
during antibiotic treatment (generally 2 to 3 weeks, depending upon the organism) or death 
during temporary hemodialysis (generally four weeks after catheter removal)”.23 
 
It is difficult to define the length of the at-risk period following peritonitis. It may be that the 
risk of mortality is elevated only during the couple of weeks of active inflammation or it may 
extend past this point. These variable and subjective approaches to diagnosing peritonitis-
associated death make it exceedingly difficult to compare, contrast and explore observed 
differences in peritonitis-associated death rates between different centres, regions and 
countries. Our results would make a case for diagnosing peritonitis-associated death as any 
death within 30 days of an episode of peritonitis. Our finding of significantly greater odds of 
peritonitis in the period just prior to death was consistent using different periods of time 
distant from death. The sensitivity analysis confirmed that this finding was not related to 
increased peritonitis risk with time on dialysis.  
 
Most studies that have examined factors that may influence patient survival in PD 
populations have failed to include peritonitis as an independent variable.2, 24-25  Sipahioglu et 
al, in their single centre retrospective study of 423 PD patients, demonstrated that for every 
increase in peritonitis rate by one episode per 12 patient months there was an associated 1.87 
fold increased relative risk of mortality.6 This was performed by entering the peritonitis rates 
into a Cox proportional hazards model which may not be appropriate as these models are not 
well suited to intermittent exposures with time-varying effects.26 This approach would also 
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have difficulties in selecting an appropriate control group (i.e. patients who did not die on 
PD). These patients are likely to be fundamentally different from those who die on PD and 
this approach may introduce control-selection biases. 
 
We chose to use a case-crossover design. This method is used to determine the relationship 
between an intermittent exposure and an outcome.27-28 A case-crossover study differs from a 
case-control study in that all participants are cases (i.e. all have experienced the outcome), all 
have had the opportunity to be exposed and unexposed at different study periods, because the 
risk posed by the exposure is transient. Rather than having case and control patients, the case-
crossover design uses case and control periods of time to determine whether the exposure 
occurs more often in the ‘case’ period, immediately before the event, than in the ‘control’ 
period/s, more distant to the outcome.27 Therefore, the case-crossover design assesses the 
timing of the exposure relative to the outcome, using participants as their own controls. 
 
The advantage of this design is that it examines the association between time-varying 
exposures on an outcome while controlling for constant patient-level confounders and 
avoiding control-selection bias.29 The main limitations of case-crossover studies are that they 
do not account for within-person (time-varying) confounders, or account for the role of 
chronic exposures.27 The design we used ensured that stable patient factors such as age, 
ethnicity and baseline co-morbidity were controlled for, however the design did not account 
for patient factors which may have changed rapidly, such as nutritional status, anaemia, or 
volume status. 
  
We selected this design given that PD patients may be repeatedly exposed and unexposed to 
peritonitis during their treatment, and that the risk of mortality posed by peritonitis is 
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unknown but it would be reasonable to assume that if an increased risk exists it is likely to be 
time-limited. The case-crossover design allowed us to determine whether peritonitis was 
more likely to occur in the period immediately before death for PD patients than during 
earlier periods. A recent paper used this methodology to identify eight potential trigger 
factors immediately prior to the rupture of intracranial aneurysms in 250 patients.30 Similarly, 
mobile phones were demonstrated to be associated with motor vehicle accidents using this 
technique .31 
 
The finding in the present investigation of an increased risk of death for up to 120 days 
following an episode of peritonitis may be potentially explained by a persistent systemic 
inflammatory state, which may predispose them to cardiovascular events.7-9, 32 This 
inflammatory state may lead to cardiovascular or cerebrovascular events that are remote to 
the time of the peritonitis.7-9 Our finding that there is a significant association between 
peritonitis and death from vascular disease is supportive of this hypothesis. There are other 
possible mechanisms explaining why peritonitis may be associated with increased mortality, 
including through its effects on increased frailty, requirement for medications, possible 
hospitalisation, and adverse effects on nutritional status.33 A further exploration is required 
into our documented association between peritonitis and death reported as Withdrawal. This 
may be mislabelling by the Registry and a better understanding of the reasons for withdrawal 
may provide additional insight into this association.  
The strengths of this study include its large sample size and inclusiveness. We included all 
patients in Australia during the study period that died whilst on PD, or within 30 days of 
transferring to haemodialysis, this greatly enhanced the external validity of our findings. In 
addition, the study methodology reduces the potential for confounding and accounts for the 
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nature of the exposure. These strengths should be balanced against the study’s limitations, the 
principal ones being that those patients sick enough to die may also be more likely to develop 
peritonitis, and that we could not adjust for rapidly-changing patient factors. Our study does 
not prove a causal link between peritonitis and mortality. In common with other Registries, 
ANZDATA is a voluntary Registry and there is no external audit of data accuracy, including 
the diagnosis of peritonitis and cause of death. Consequently, the possibility of 
coding/classification bias cannot be excluded. It is also possible that physicians report 
peritonitis events more often when they occur in close proximity to death. The study design 
also will not correct for any potential time-varying confounders. As the data for this study is 
obtained from a single region, and limited to those patients that had been on PD for a 
minimum of 7 months, the results may not necessarily be generalizable to other PD 
populations.  
 
In conclusion, we have established for the first time that there is a significant association 
between mortality and peritonitis. We recommend that a new definition of peritonitis-
associated mortality be made that includes any death within 30 days following an episode of 





All patients on the Australia and New Zealand Dialysis and Transplant (ANZDATA) 
Registry that died on PD or within 30 days of transferring from PD to hemodialysis, between 
1st May 2004 and 31st December 2009 were included in this study. Patients also had to be on 
PD for a minimum of 7 months to allow a control period of time, distant to the time of death, 
to compare the peritonitis rates with. Ethics approval was received from The University of 
Western Australia. 
 
The start date for peritonitis was defined as the date of diagnosis, based upon clinical features 
of peritonitis (abdominal pain or cloudy dialysate) and dialysate leukocytosis (white blood 
cell count > 100 /µL with > 50% neutrophils).34 Variables collected from the ANZDATA 
Registry included dates of all diagnosis of peritonitis, patient demographic characteristics (ie. 
age at time of death, gender, race, geographic remoteness at commencement of dialysis) and 
clinical characteristics (ie. body mass index (BMI), cause of primary renal disease, co-
morbidities at the start of dialysis, smoking status, Kt/V, membrane transport characteristics 
and cause of death). These data are collected by nursing and medical staff in each renal unit 
in Australia and New Zealand and are submitted to the ANZDATA Registry annually. 
 
Statistical analysis 
We used a time-stratified case-crossover design whereby each patient acted as his or her own 
control (Figure 4).11, 35 Two sampling periods were determined – i) the ‘case’ window, 
immediately prior to the patient’s death, and ii) a ‘control’ window, of equal duration, distant 
from the time of death. We varied the duration of these windows and the distance from the 
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time of death in our analyses. Conditional logistic regression was used to compare the odds 
of peritonitis in the 'case' window compared with the 'control' window for the same patient. 
This method eliminated the influence of stable patient-level confounders, such as sex, race 
and comorbidities. This method was used to assess the association between peritonitis and 
all-cause mortality, death due to vascular disease (defined as death due to cardiovascular, 
cerebrovacular or peripheral vascular disease), death due to infection and death due to 
withdrawal of dialysis. Cause of death was defined by the treating physician. 
 
Peritonitis may be more likely to occur the longer a patient is on dialysis, so a sensitivity 
analysis was performed examining the relative risk of peritonitis in two 30 day windows that 
are both distant from the time of death, including 6, 9 and 12 months. Another sensitivity 
analysis was performed examining patients with one episode separately to patients with 
multiple episodes of peritonitis. 
 
Logistic regression was used to determine the patient demographic and clinical characteristics 
predictive of peritonitis in the 30 days before death. Univariate models were initially used to 
examine the relationship between each variable and peritonitis within 30-days of death. The 
categorical variables examined were sex, age group (<60, 60-74, ≥75), state of residence, 
Aboriginal or Torres Strait Islander status, BMI category (underweight <20, healthy 20-24.9, 
overweight 25-29.9, obese ≥30), smoking status (current, former or never), membrane 
transport status category (low <0.50, low average 0.50-0.64, high average 0.65-0.80, high 
≥0.81), and comorbid  diabetes, chronic lung disease, coronary heart disease, peripheral 
vascular disease, and cerebrovascular disease (yes/no). The continuous variables examined 
were time on PD (years) and number of peritonitis episodes. The linearity assumption was 
tested by examining the interaction between these variables and their log transformations, and 
15 
was not violated in either case.36 Those variables significantly predicting peritonitis within 30 
days of death (p <0.05) were included in a multivariate logistic regression model (coronary 
heart disease, time on PD and number of peritonitis episodes).  
 
Conditional logistic regression analyses were conducted in SAS version 9.2. All other 
statistical procedures were conducted in IBM SPSS Statistics version 19. 
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Figure 2b: Odds of peritonitis in 
different 7-day periods prior to 
death compared with all other 
preceding 7-day periods in the 
year before death. 
 
Figure 2a: Odds of peritonitis in 
different 5-day periods prior to 
death compared with all other 
preceding 5-day periods in the 




Figure 3 a. Odds of peritonitis in 
different 30-day periods prior to 
death from vascular disease  
compared with all other 
preceding 30-day periods in the 






Figure 3 b. Odds of peritonitis in 
different 30-day periods prior to 
death from Infection compared 
with all other preceding 30-day 








Figure 3 c. Odds of peritonitis in 
different 30-day periods prior to 
death from Withdrawal from 
dialysis compared with all other 
preceding 30-day periods in the 












Figure 4. Case-crossover method in which individual patients serve as their own control. The 
odds of peritonitis occurring within the case window (period immediately before death), 
which can be of varying lengths, is compared to a control window (period remote from death, 




Female 582 (44.2%) 
Age at start of Peritoneal Dialysis (PD) (years) 67.5 (11.8) # 
Age at death (years) 70.4 (11.7) # 
Time on PD (years) 2.3 (1.4-3.9)* 
State of residence: 
    New South Wales & Australian Capital 
Territory 
    Victoria 
    Western Australia 
    Queensland 
    Tasmania 
    South Australia 






  21 (1.6%) 
  88 (6.7%) 
  21 (1.6%) 
Region of residence: 
    Major city 
    Regional 
    Remote 








    Caucasian 
    Asian 
    Pacific 
    Aboriginal and Torres Strait Islander 
 
1023 (77.8%) 
  141 (10.7%) 
    34 (2.6%) 
  117 (8.9%) 
Cause of death: 
  Peritonitis 
  Other infection 
  Cardiac 
  Cerebrovascular 
  Peripheral vascular 
  Malignancy  
  Withdrawal 
  Other 
 
   78 (5.9%) 
 115 (8.7%) 
 578 (43.9%) 
 107 (8.1%) 
   48 (3.6%) 
   96 (7.3%) 
 174 (13.2%) 
 120 (9.1%) 
Number of peritonitis episodes: 
  None 
  One 
  Two 






Median days from peritonitis to death 247 (64-552)* 
26 
Smoking status 
  Current 
  Former 





Body Mass Index (kg/m2): 
    <20 
    20.0-24.9 
    25.0-29.9 
    ≥30 
 






  Type I 
  Type II non-insulin requiring 
  Type II insulin requiring  
 
 




  Chronic Lung Disease 
  Coronary Artery Disease 
  Peripheral Vascular Disease 
  Cerebrovascular Disease 








Membrane transport status 
  Low 
  Low average 
  High average 
  High 
  Unknown 
   





Kt/V (total)   1.8 (0.6) # 
 
 
Table 1: Cohort demographic and clinical characteristics. 
# mean (standard deviation) 





Table 2: Odds ratio of peritonitis in the 30-days prior to death compared to the 
30-day period 3, 6 and 9 months prior to death (with 95% confidence intervals). 
Comparator month Odds ratio 95% confidence intervals 
All patients   
3 months 4.07  a 3.04-5.45 
6 months 6.23 a 4.44-8.74 
9 months 6.97 b 4.84-10.04 
 
Patients with 1 episode   
3 months 8.36 c 4.80-14.55 
6 months 5.09 c 3.25-7.95 







Table 3: Sensitivity analysis comparing the odds ratio of peritonitis in a 30-day window at two 
different periods of time prior to death 
 Odds ratio 95% confidence intervals 
All patients   
6 months versus 9 months 0.95 a 0.64-1.48 
6 months versus 12 months 0.81 b 0.51-1.27 
 
Patients with 1 episode 
  
6 months versus 9 months 1.10 c 0.47-2.59 








Table 4: Results from logistic regression showing odds of peritonitis in the 30-days prior to 
death for selected patient demographic and clinical characteristicsa. 
 Odds ratio 95% confidence 
intervals 
P-value 
History of coronary 
artery disease 
0.71 0.51-0.99 0.048 
Time on peritoneal 
dialysis (years)b 
1.07 1.00-1.15 0.049 
Number of peritonitis 
casesb 
1.71 1.55-1.89 <0.001 
a: N = 1316. 
b: Odds ratios refer to each unit increase. 
